CABALETTA BIO DL -,00001

Cabaletta Bio reported a net loss per share of $0.73 for Q2 2026, a deterioration of about 30% year‑over‑year driven by higher spending on late‑stage clinical development. The company holds roughly $225.1 million in cash following a registered direct placement but sees funding secured only through mid‑2027, signaling potential dilution risks ahead of a BLA filing. Clinically, positive Phase‑1/2 data were reported with 80% reaching the primary endpoint in the approval cohort of adult patients with dermatomyositis and antisynthetase syndrome, and ElevateBio was engaged as a second CDMO. Despite operational progress, the stock has come under pressure and is trading intraday weaker than the broader market. » Más en de.investing.com

Cabaletta Bio reported positive clinical and translational results from the first four patients in the lowest-dose cohort evaluating preconditioning-free (PC-free) rese-cel, with 50% of patients showing drug-free responses for six months. Manufacturing and translational data from two autoimmune patients treated using the Cellares Cell Shuttle were also presented, and the company found a higher rese-cel dose may be required without preconditioning. Cabaletta has signed a long-term commercial supply agreement to enable large-scale, low-cost production and is preparing initial data from lupus patients dosed with preconditioning while advancing rese-cel toward a BLA and potential commercial launch. » Más en finance.yahoo.com

Cabaletta Bio reports positive clinical results for the cell therapy rese‑cel at a rheumatology congress: in the RESET‑myositis study 83% of dermatomyositis patients achieved a moderate to strong response after 16 weeks, which persisted at follow‑up for up to 1.5 years. In systemic sclerosis, a cohort with interstitial lung disease showed a median improvement in forced vital capacity of 7.5% after 36 weeks; in lupus, remissions and strong B‑cell depletions were observed. Cabaletta plans to start a single‑arm registration study in systemic sclerosis in Q4 2026 and aims to report topline data for dermatomyositis in mid‑2027; the stock is up 68% year‑to‑date, the company has a current ratio of 2.95 and an annual cash burn of about $143m. » Más en de.investing.com